INSYQ Plunges Nearly 10% Despite FDA Approving New Drug Application
Insys Therapeutics (OTCPK:INSYQ) experienced a whirlwind in the past months, from witnessing a 48% drop in Q4 revenue and paying a $225 million settlement that sent INSY stock up 12% to jumping 240% after receiving ... [Read]
INSY Stock Jumps 240%: Gets “First Day” Motion After Chapter 11 Filing
Insys Therapeutics (NASDAQ:INSY) is back in the news this week, after agreeing last Friday to pay a $225 million settlement to resolve criminal investigations regarding its role in marketing opioids, an addictive painkiller. This week, ... [Read]
INSY Stock Rises 12% After Paying $225M to Settle Opioid Investigations
Trying times for Insys Therapeutics (NASDAQ:INSY) have finally come to an end—but at a price. On Friday, the opioid manufacturer said it has agreed to pay a whopping $225 million to settle criminal investigations. And ... [Read]
INSY Down After Insys Therapeutics Announces 48% Drop in Q4 Revenue
On Thursday, March 7th, pharmaceutical cannabis company Insys Therapeutics (NASDAQ:INSY) announced its Q4 financial results. Despite taking steps to become a leader in the pharmaceutical-grade cannabinoids sector, INSY saw a nearly 48% drop in net revenue ... [Read]